Hyperion Therapeutics (FRA:0HY) ROCE % : 24.97% (As of Mar. 2015)

View and export this data going back to . Start your Free Trial

What is Hyperion Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hyperion Therapeutics's annualized ROCE % for the quarter that ended in Mar. 2015 was 24.97%.

Hyperion Therapeutics ROCE % Historical Data

The historical data trend for Hyperion Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hyperion Therapeutics ROCE % Chart

Hyperion Therapeutics Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

ROCE %

-272.14

21.90

-3.34

Hyperion Therapeutics Quarterly Data
	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15
ROCE %	Get a 7-Day Free Trial													5.31	32.77	-60.05	18.70	24.97

Hyperion Therapeutics ROCE % Calculation

Hyperion Therapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2014 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2014 )		(A: Dec. 2013 )		(A: Dec. 2014 )
	=	-3.529	/	( ( (104.039 - 14.696)	+	(146.317 - 24.656) )	/ 2 )
	=	-3.529	/	( (89.343	+	121.661)	/ 2 )
	=	-3.529	/	105.502
	=	-3.34 %

Hyperion Therapeutics's ROCE % of for the quarter that ended in Mar. 2015 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2015 )		(Q: Dec. 2014 )		(Q: Mar. 2015 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2015 )		(Q: Dec. 2014 )		(Q: Mar. 2015 )
	=	33.324	/	( ( (146.317 - 24.656)	+	(180.208 - 34.984) )	/ 2 )
	=	33.324	/	( ( 121.661	+	145.224 )	/ 2 )
	=	33.324	/	133.4425
	=	24.97 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2015) EBIT data.

Hyperion Therapeutics (FRA:0HY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hyperion Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Hyperion Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hyperion Therapeutics (FRA:0HY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hyperion Therapeutics Inc (FRA:0HY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hyperiontx.com

Hyperion Therapeutics Inc., was incorporated in Delaware on November 1, 2006. The Company completed its initial public offering on July 2012. It is a commercial biopharmaceutical company, engaged in the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology. Its products, RAVICTI (glycerol phenylbutyrate) Oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) Tablets and Powder, are designed to lower ammonia in the blood. The Company has developed RAVICTI to treat urea cycle disorders including 7 of the 8 prevalent UCD subtypes, and is developing glycerol phenylbutyrate, the active pharmaceutical ingredient in RAVICTI, to treat hepatic encephalopathy. RAVICTI is indicated for use as a nitrogen-binding agent for chronic management of adult and pediatric patients above 2 years of age with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. It distributes RAVICTI through two specialty pharmacies with a single dedicated call center responsible for interfacing with patients, physicians and payors. BUPHENYL is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. The Company faces competition from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions, among others, which may in the future develop products to treat UCD or HE. The Company is subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances.

Hyperion Therapeutics (FRA:0HY) Headlines

No Headlines